Cancer and necroptosis: friend or foe?

被引:58
|
作者
Philipp, Stephan [1 ]
Sosna, Justyna [1 ]
Adam, Dieter [1 ]
机构
[1] Univ Kiel, Inst Immunol, Michaelisstr 5, D-24105 Kiel, Germany
关键词
Regulated necrosis; Necroptosis; Cancer; TRAIL; TNF; PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; MIXED LINEAGE KINASE; DOMAIN-LIKE PROTEIN; TRAIL RECEPTOR; TNF-ALPHA; APOPTOSIS; RIP3; EXPRESSION; FADD;
D O I
10.1007/s00018-016-2193-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Regulated cell death is one major factor to ensure homoeostasis in multicellular organisms. For decades, apoptosis was considered as the sole form of regulated cell death, whereas necrosis was believed to be accidental and unregulated. Due to this view, research on necrosis was somewhat neglected, especially in the field of anti-cancer treatment. However, new interest in necrosis has been sparked by the recent discovery of different forms of necrosis that show indeed regulated pathways. More and more studies now address the molecular pathways of regulated necrosis and its connections within the cellular signaling networks. Necroptosis, a subform of regulated necrosis, has so far hardly been focused on with regard to a future treatment of cancer patients and may emerge as a novel and effective approach to eliminate tumor cells. However, and similar to apoptosis, tumor cells can develop resistances against necroptosis to ensure their own survival. In this context, new molecules that enhance necroptosis are currently being identified to overcome such resistances. This review discusses cancer and necroptosis as friends or foes, i.e. the options to exploit necroptosis in anti-cancer therapies ("foes"), but also potential limitations that may block or actually cause necroptosis to act in a protumoral manner ("friends"). The balance between these two possible roles will determine whether necroptosis can indeed be used as a promising tool for early diagnosis of tumors, prevention of metastasis and anti-cancer treatment.
引用
下载
收藏
页码:2183 / 2193
页数:11
相关论文
共 50 条
  • [41] Vitamin C: Cancer's friend or foe?
    Aldhous, Peter
    NEW SCIENTIST, 2008, 199 (2668) : 10 - 10
  • [42] The immune system in cancer metastasis: friend or foe?
    Janssen, Louise M. E.
    Ramsay, Emma E.
    Logsdon, Craig D.
    Overwijk, Willem W.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [43] Glucocorticoids and prostate cancer treatment: friend or foe?
    Montgomery, Bruce
    Cheng, Heather H.
    Drechsler, James
    Mostaghel, Elahe A.
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 354 - 358
  • [44] Diabetic Ferroptosis and Pancreatic Cancer: Foe or Friend?
    Li, Le
    Yu, Xing-jia
    Gao, Lei
    Cheng, Long
    Sun, Bei
    Wang, Gang
    ANTIOXIDANTS & REDOX SIGNALING, 2022, 37 (16) : 1206 - 1221
  • [45] Friend or foe?: The proteasome in combined cancer therapy
    Sohn, Dennis
    Totzke, Gudrun
    Schulze-Osthoff, Klaus
    Jaenicke, Reiner U.
    CELL CYCLE, 2006, 5 (08) : 841 - 845
  • [46] Desmoplastic reaction in pancreatic cancer: Friend or foe?
    Apte, Minoti V.
    Pirola, Ron C.
    Wilson, Jeremy S.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2006, 30 (09) : 58A - 58A
  • [47] Revisiting ovarian cancer microenvironment: a friend or a foe?
    Zhang, Boyi
    Chen, Fei
    Xu, Qixia
    Han, Liu
    Xu, Jiaqian
    Gao, Libin
    Sun, Xiaochen
    Li, Yiwen
    Li, Yan
    Qian, Min
    Sun, Yu
    PROTEIN & CELL, 2018, 9 (08) : 674 - 692
  • [48] GLP1 and cancer: friend or foe?
    Vangoitsenhoven, Roman
    Mathieu, Chantal
    Van der Schueren, Bart
    ENDOCRINE-RELATED CANCER, 2012, 19 (05) : F77 - F88
  • [49] Molecular Pathways: Is AMPK a Friend or a Foe in Cancer?
    Hardie, D. Grahame
    CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3836 - 3840
  • [50] Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?
    McCann, Christopher
    Kerr, Emma M.
    CANCERS, 2021, 13 (13)